Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
21 sept. 2021 08h00 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Pharmaceuticals Announces Convertible Notes Repurchase
13 sept. 2021 08h00 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference
01 sept. 2021 08h00 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
10 août 2021 21h43 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
29 juil. 2021 07h00 HE
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to...
Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
19 juil. 2021 07h00 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
21 juin 2021 08h00 HE
|
Intercept Pharmaceuticals, Inc.
New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with...
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
15 juin 2021 08h00 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
09 juin 2021 08h00 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints Andrew Saik as Chief Financial Officer
07 juin 2021 08h00 HE
|
Intercept Pharmaceuticals, Inc.
NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...